Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile

Subjects

Subjects :

Cancer Research
Chemotherapy
business.industry
medicine.medical_treatment
Myeloid leukemia
Hematology
Safety profile
Oncology
Relapsed refractory
medicine
Cancer research
business
Tyrosine kinase
Flt3 itd

Details

ISSN :

21522650

Volume :

18

Database :

OpenAIRE

Journal :

Clinical Lymphoma Myeloma and Leukemia

Accession number :

edsair.doi...........7131543b1049a4c11c6f2bcbe1a5cb24

Full Text :

https://doi.org/10.1016/j.clml.2018.07.048